US 9,809,648 B2
Engineered anti-IL-23p19 antibodies
Leonard G. Presta, Palo Alto, CA (US); Brian M. Beyer, Kenilworth, NJ (US); Richard N. Ingram, Kenilworth, NJ (US); Peter Orth, Kenilworth, NJ (US); and Yan-Hui Liu, Kenilworth, NJ (US)
Assigned to Merck Sharp & Dohme Corp., Rahway, NJ (US)
Filed by MERCK SHARP & DOHME CORP., Rahway, NJ (US)
Filed on Dec. 17, 2012, as Appl. No. 13/717,131.
Application 13/717,131 is a continuation of application No. 13/031,544, filed on Feb. 21, 2011, granted, now 8,404,813.
Application 13/031,544 is a continuation of application No. 12/526,543, granted, now 8,293,883, previously published as PCT/US2008/002333, filed on Feb. 21, 2008.
Claims priority of provisional application 60/891,409, filed on Feb. 23, 2007.
Prior Publication US 2013/0122009 A1, May 16, 2013
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); C07K 16/24 (2006.01); C07K 14/54 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [C07K 14/54 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)] 12 Claims
 
1. A monoclonal antibody or antigen binding fragment thereof, that binds to human IL-23 at an epitope comprising residues 20-30 and 82-110 of SEQ ID NO: 47, wherein the antibody or antigen binding fragment thereof comprises:
a) a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
i) CDRL1 comprises the sequence of SEQ ID NO: 36;
ii) CDRL2 comprises the sequence of SEQ ID NO: 41; and
iii) CDRL3 comprises the sequence of SEQ ID NO: 46;
and
b) a heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein:
i) CDRH1 comprises the sequence of SEQ ID NO: 19;
ii) CDRH2 comprises a sequence selected from the group consisting of SEQ ID NOs: 24-26; and
iii) CDRH3 comprises the sequence of SEQ ID NO: 31.